Discovery & Aerogen tackle respiratory disease:
This article was originally published in Clinica
Executive Summary
Discovery Laboratories, of Doylestown, Philadelphia, and Aerogen will evaluate Aerogen's Aeroneb Pro system as a means for pulmonary delivery of Discovery's Surfaxin humanised lung surfactant in hospitalised, mechanically ventilated patients. Aerosolised surfactant therapies, which are used in patients with respiratory disease to improve the lungs' ability to absorb oxygen, represent a worldwide market of $5bn, the companies note. Aerogen, of Mountain View, California, believes that the collaboration could markedly improve respiratory drug therapy in the critical care setting.